Between 70 and 75 percent of patients with myelodysplastic syndromes, also known as MDS, eventually die from complications of the disease or progression to cancer, explains the Neutropenia Support Association. MDS progresses to acute myeloid leukemia in roughly 30 percent of patients.
MDS refers to a group of blood disorders in which the body's bone marrow does not produce enough mature or functioning red blood cells, white blood cells or platelets, according to the Johns Hopkins School of Medicine. MDS effects between 20,000 to 30,000 people annually in the United States as of 2015 and occurs more commonly in those over the age of 50. Symptoms of MDS include fatigue and shortness of breath during physical activity, weight loss, fever and loss of appetite.